Moberg Pharma AB (publ) (STO:MOB)
Sweden · Delayed Price · Currency is SEK | Market Cap | 471.42M +14.9% |
| Revenue (ttm) | 13.54M +38.0% |
| Net Income | -27.24M |
| EPS | -0.58 |
| Shares Out | 47.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,336 |
| Average Volume | 104,480 |
| Open | 10.14 |
| Previous Close | 10.03 |
| Day's Range | 10.06 - 10.40 |
| 52-Week Range | 6.52 - 12.10 |
| Beta | 1.18 |
| RSI | 44.32 |
| Earnings Date | May 12, 2026 |
About Moberg Pharma AB
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden. [Read more]
Full Company ProfileFinancial Performance
In 2025, Moberg Pharma AB's revenue was 13.54 million, an increase of 37.99% compared to the previous year's 9.81 million. Losses were -27.24 million, -89.32% less than in 2024.
Financial StatementsNews
Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
STOCKHOLM , Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Eur...
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
STOCKHOLM , Dec. 10, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing ...
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
STOCKHOLM , Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Pha...
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%
STOCKHOLM , June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinar...